Loading...
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Libertas Academica
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2902205/ https://ncbi.nlm.nih.gov/pubmed/20711245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|